A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) for Subcutaneous Administration in Subjects With Type 2 Diabetes
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Insulin icodec (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
- 22 Dec 2017 Status changed from recruiting to completed.